Literature DB >> 24244086

THE PARADOXICAL EFFECT ON PNEUMONIA OF CHRONIC INHALED CORTICOSTEROIDS.

Oriol Sibila1, Antonio Anzueto, Marcos I Restrepo.   

Abstract

Community-acquired pneumonia (CAP) is the leading infectious cause of death in developed countries. Several studies have shown that the risk of pneumonia is increased in patients with Chronic Obstructive Pulmonary Disease (COPD) who are receiving chronic inhaled corticosteroids (ICS). The impact of ICS On pneumonia prognosis is controversial. Recent studies have shown that COPD patients with prior ICS use have less mortality after developing CAP as compared with patients with COPD without prior ICS use. This review discusses the association of ICS and the risk of CAP and its association with clinical outcomes in patients with COPD and pneumonia.

Entities:  

Year:  2013        PMID: 24244086      PMCID: PMC3828120          DOI: 10.1097/CPM.0b013e31827a2a60

Source DB:  PubMed          Journal:  Clin Pulm Med


  45 in total

1.  Bronchoalveolar lavage cellular profiles in lung transplantation: the effect of inhaled corticosteroids.

Authors:  H Whitford; B Orsida; T Kotsimbos; M Pais; C Ward; L Zheng; T Williams; E H Walters; G Snell
Journal:  Ann Transplant       Date:  2000       Impact factor: 1.530

Review 2.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

Review 3.  Inhaled corticosteroids: impact on asthma morbidity and mortality.

Authors:  S Suissa; P Ernst
Journal:  J Allergy Clin Immunol       Date:  2001-06       Impact factor: 10.793

4.  Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study.

Authors:  M H Brutsche; I C Brutsche; M Munawar; S J Langley; C M Masterson; P T Daley-Yates; R Brown; A Custovic; A Woodcock
Journal:  Lancet       Date:  2000-08-12       Impact factor: 79.321

Review 5.  Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma.

Authors:  M Sharpe; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis.

Authors:  B J Lipworth
Journal:  Arch Intern Med       Date:  1999-05-10

7.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.

Authors:  Peter Calverley; Romain Pauwels; Jørgen Vestbo; Paul Jones; Neil Pride; Amund Gulsvik; Julie Anderson; Claire Maden
Journal:  Lancet       Date:  2003-02-08       Impact factor: 79.321

8.  Inhaled and nasal corticosteroid use and the risk of fracture.

Authors:  Samy Suissa; Marc Baltzan; Richard Kremer; Pierre Ernst
Journal:  Am J Respir Crit Care Med       Date:  2003-10-09       Impact factor: 21.405

9.  Population pharmacokinetics and pharmacodynamics of ciclesonide.

Authors:  S Rohatagi; V Arya; K Zech; R Nave; G Hochhaus; B K Jensen; J S Barrett
Journal:  J Clin Pharmacol       Date:  2003-04       Impact factor: 3.126

10.  Chronic obstructive pulmonary disease surveillance--United States, 1971-2000.

Authors:  David M Mannino; David M Homa; Lara J Akinbami; Earl S Ford; Stephen C Redd
Journal:  MMWR Surveill Summ       Date:  2002-08-02
View more
  2 in total

Review 1.  Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?

Authors:  Emir Festic; Paul D Scanlon
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

Review 2.  Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis.

Authors:  Emir Festic; Vikas Bansal; Ena Gupta; Paul D Scanlon
Journal:  COPD       Date:  2015-12-08       Impact factor: 2.409

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.